Actuate Therapeutics Stock Forecast

Stock Price Forecast

The 2 analysts with 12-month price forecasts for Actuate Therapeutics stock have an average target of 20, which predicts a 136.97% increase from the current stock price of 8.44.

Price Target: $20 (+136.97%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$20	$20	$20	$20
Change	+136.97%	+136.97%	+136.97%	+136.97%

Analyst Ratings

The average analyst rating for Actuate Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	1	1	1	2
Buy	0	0	0	0
Hold	0	0	0	0
Sell	0	0	0	0
Strong Sell	0	0	0	0
Total	1	1	1	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Mayank Mamtani B. Riley Securities	B. Riley Securities	Strong Buy Initiates $20	Strong Buy	Initiates	$20	+136.97%	Aug 26, 2025
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $20	Strong Buy	Reiterates	$20	+136.97%	Aug 18, 2025
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Initiates $20	Strong Buy	Initiates	$20	+136.97%	Mar 17, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-1.16

from -3.26

EPS Next Year

-1.34

from -1.16

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	-	-	-	-
Revenue Growth	-	-	-	-	-	-
EPS	-16.65	-17.24	-3.26	-1.16	-1.34	-1.73
EPS Growth	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-
No. Analysts	-	-	-	5	5	5

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026
High	n/a	n/a
Avg	n/a	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2025	2026
High	-1.10	-1.07
Avg	-1.16	-1.34
Low	-1.18	-1.48

EPS Growth

EPS Growth	2025	2026
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.